Biopharmaceutical investment only reaching 1/10 of other competing countries
After the Korea Exchange created the ‘Exceptional Listing Clause through Technology Evaluation’ on December 2005, the total 27 biotechnology companies have acquired approval to go public through it until the end of 2015, and all of them were listed.
Biopharmaceutical companies which did not meet...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
